Long-acting injectable antipsychotic use in patients with bipolar disorder: Findings from the REAP-BD study

This publication has 24 references indexed in Scilit:

• A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review
  Psychiatry Research, 2024
• Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study
  Asian Journal of Psychiatry, 2023
• Taiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 update
  Asian Journal of Psychiatry, 2023
• Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: A retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study
  Journal of Affective Disorders, 2022
• Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
  CNS Drugs, 2021
• Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review
  CNS Drugs, 2019
• Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
  European Neuropsychopharmacology, 2019
• Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database
  Journal of Affective Disorders, 2017
• Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder
  Journal of Affective Disorders, 2016
• A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder
  European Neuropsychopharmacology, 2012